Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Sandoz Gets Broader Label for Genotropin Biosimilar
August 20, 2026
- Mochida to Take Over Topiloric from Fuji Yakuhin in October
August 20, 2026
- Eisai CEO Honored by WashU Medicine for AD Contributions
August 20, 2026
- MSD Revises Airwin Label with ZENITH Trial Data
August 20, 2026
- Opdivo Snares Taiwan Label Expansion for NSCLC: Ono
August 20, 2026
- Keytruda Keeps Top Spot in Japan in April-June as Mounjaro Zooms: IQVIA
August 19, 2026
- LEO Pharma Buys Global Rights to Tanabe’s EPP/XLP Drug
August 19, 2026
- J-TEC to Explore Regenerative Medicine Licensing Opportunities in Taiwan
August 19, 2026
- Shionogi to Effectively Scrap Mandatory Retirement from FY2027
August 19, 2026
- Chugai Out-Licenses Anti-Dengue Antibody AID351 to GSK
August 19, 2026
- Eisai Maps Out Next-Gen Alzheimer’s Strategy beyond Leqembi
August 18, 2026
- Enhertu Hits PIII Primary Goal in 1st-Line HER2-Mutant NSCLC
August 18, 2026
- Enhertu Combo Scores China Nod in 1st-Line HER2 Breast Cancer
August 18, 2026
- Santen Releases Glaucoma Drug Rhopressa in Japan
August 18, 2026
- Yaz AGs Now Available in Japan, Hisamitsu Handling Distribution
August 18, 2026
- Organon Dysmenorrhea Drug Mercilon Set for Sept. 1 Launch
August 18, 2026
- Pfizer, BioNTech Win Japan Nod for XFG-Adapted COVID Vaccines
August 18, 2026
- 3D Seeks Injunction against Toho’s Poison Pill
August 18, 2026
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Chugai Files Tecentriq for Colon Cancer Adjuvant Therapy in Japan
August 17, 2026
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…